Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort

BACKGROUND: The benefits of pembrolizumab in patients with advanced urothelial carcinoma (UC) and impaired performance status (PS) remain unknown. This study assessed the safety and efficacy of pembrolizumab in patients with platinum‐refractory UC and Eastern Cooperative Oncology Group PS ≥2 to iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Katsuhiro, Kobayashi, Takashi, Kojima, Takahiro, Hikami, Kensuke, Yamada, Takeshi, Ogawa, Kosuke, Nakamura, Kenji, Sassa, Naoto, Yokomizo, Akira, Abe, Takashige, Tsuchihashi, Kazunari, Tatarano, Shuichi, Inokuchi, Junichi, Tomida, Ryotaro, Fujiwara, Maki, Takahashi, Atsushi, Matsumoto, Kazumasa, Shimizu, Kosuke, Araki, Hiromasa, Kurahashi, Ryoma, Osaki, Yu, Tashiro, Yu, Uegaki, Masayuki, Ogawa, Osamu, Kitamura, Hiroshi, Nishiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124127/
https://www.ncbi.nlm.nih.gov/pubmed/33931987
http://dx.doi.org/10.1002/cam4.3863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124127/
https://www.ncbi.nlm.nih.gov/pubmed/33931987
http://dx.doi.org/10.1002/cam4.3863

Ejemplares similares